Molecular and cellular mechanisms underlying anti-neuronal antibody mediated disorders of the central nervous system

Autoimmunity Reviews

Volumn 13, Issue 3, 2014, Pages 299-312

  Van Coevorden Hameete, M H ^a   de Graaff, E ^a   Titulaer, M J ^b   Hoogenraad, C C ^a   Sillevis Smitt, P A E ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antibody; Autoimmune encephalitis; Cell surface antigen; Central nervous system; Ion channel; Neurotransmitter receptor

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMPA RECEPTOR; ANTIBODY; CASPR2 PROTEIN; DNER PROTEIN; DOPAMINE RECEPTOR; DPP6 PROTEIN; G PROTEIN COUPLED RECEPTOR; GLYCINE RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; LIGAND GATED ION CHANNEL; MEMBRANE PROTEIN; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 5; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUREXIN; NEURONAL ANTIBODY; POTASSIUM CHANNEL; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

ANTIBODY STRUCTURE; ANTIGEN STRUCTURE; BRAIN REGION; CELL FUNCTION; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR PATHOLOGY; MYOKYMIA; NEUROLOGIC DISEASE; PARANEOPLASTIC NEUROPATHY; PATHOGENICITY; PHENOTYPE; PROTEIN MODIFICATION; REVIEW;

ANTIBODY; AUTOIMMUNE ENCEPHALITIS; CELL SURFACE ANTIGEN; CENTRAL NERVOUS SYSTEM; ION CHANNEL; NEUROTRANSMITTER RECEPTOR;

ANIMALS; ANTIBODIES; ANTIGENS; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; ION CHANNELS; NEURONS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84891741312     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.10.016     Document Type: Review

References (192)

1. Szabo A., et al. HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and sex-lethal. Cell 1991, 67(2):325-333.
2. Sillevis Smitt P., et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 2000, 342(1):21-27.
3. Dalmau J., et al. Paraneoplastic anti-N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007, 61(1):25-36.
4. Bataller L., et al. Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor. Neurology 2010, 74(3):265-267.
5. Lancaster E., et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010, 9(1):67-76.
6. de Graaff E., et al. Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol 2012, 71(6):515-524.
7. Iorio R., Lennon V.A. Neural antigen-specific autoimmune disorders. Immunol Rev 2012, 248(1):104-121.
8. Rosenfeld M.R., Dalmau J. Diagnosis and management of paraneoplastic neurologic disorders. Curr Treat Options Oncol 2013, 14(4):528-538.
9. Witebsky E., et al. Chronic thyroiditis and autoimmunization. J Am Med Assoc 1957, 164(13):1439-1447.
10. Drachman D.B. How to recognize an antibody-mediated autoimmune disease: criteria. Res Publ Assoc Res Nerv Ment Dis 1990, 68:183-186.
11. Xu S.Z., et al. Generation of functional ion-channel tools by E3 targeting. Nat Biotechnol 2005, 23(10):1289-1293.
12. Mikasova L., et al. Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain 2012, 135(Pt 5):1606-1621.
13. Boyse E.A., Stockert E., Old L.J. Modification of the antigenic structure of the cell membrane by thymus-leukemia (TL) antibody. Proc Natl Acad Sci U S A 1967, 58(3):954-957.
14. Dalmau J., et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008, 7(12):1091-1098.
15. Hughes E.G., et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010, 30(17):5866-5875.
16. Conti-Fine B.M., Milani M., Kaminski H.J. Myasthenia gravis: past, present, and future. J Clin Invest 2006, 116(11):2843-2854.
17. Diamond B., et al. Losing your nerves? Maybe it's the antibodies. Nat Rev Immunol 2009, 9(6):449-456.
18. Irani S.R., Vincent A. NMDA receptor antibody encephalitis. Curr Neurol Neurosci Rep 2011, 11(3):298-304.
19. Peery H.E., et al. Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology. Autoimmun Rev 2012, 11(12):863-872.
20. Titulaer M.J., et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013, 12(2):157-165.
21. Dalmau J., et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011, 10(1):63-74.
22. Hunt D.L., Castillo P.E. Synaptic plasticity of NMDA receptors: mechanisms and functional implications. Curr Opin Neurobiol 2012, 22(3):496-508.
23. Waxman E.A., Lynch D.R. N-methyl-d-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neuroscientist 2005, 11(1):37-49.
24. Monaghan D.T., et al. Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators. Neurochem Int 2012, 61(4):581-592.
25. Monyer H., et al. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 1994, 12(3):529-540.
26. Huggins D.J., Grant G.H. The function of the amino terminal domain in NMDA receptor modulation. J Mol Graph Model 2005, 23(4):381-388.
27. Paoletti P. Molecular basis of NMDA receptor functional diversity. Eur J Neurosci 2011, 33(8):1351-1365.
28. Karakas E., Simorowski N., Furukawa H. Structure of the zinc-bound amino-terminal domain of the NMDA receptor NR2B subunit. EMBO J 2009, 28(24):3910-3920.
29. Tuzun E., et al. Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol 2009, 118(6):737-743.
30. Gleichman A.J., et al. Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain. J Neurosci 2012, 32(32):11082-11094.
31. Pruss H., et al. IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment. Neurology 2012, 78(22):1743-1753.
32. Hammer C., et al. Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Mol Psychiatry 2013, [E-pub ahead of print].
33. Steiner J., et al. Increased prevalence of diverse N-methyl-d-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-d-aspartate glutamate receptor encephalitis. JAMA Psychiatry 2013, 70(3):271-278.
34. Lauvsnes M.B., Omdal R. Systemic lupus erythematosus, the brain, and anti-NR2 antibodies. J Neurol 2012, 259(4):622-629.
35. Mohn A.R., et al. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999, 98(4):427-436.
36. Abi-Saab W.M., et al. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 1998, 31(Suppl. 2):104-109.
37. Iizuka T., et al. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology 2008, 70(7):504-511.
38. Ishiura H., et al. Response of anti-NMDA receptor encephalitis without tumor to immunotherapy including rituximab. Neurology 2008, 71(23):1921-1923.
39. Seki M., et al. Neurological response to early removal of ovarian teratoma in anti-NMDAR encephalitis. J Neurol Neurosurg Psychiatry 2008, 79(3):324-326.
40. Frechette E.S., et al. Prolonged follow-up and CSF antibody titers in a patient with anti-NMDA receptor encephalitis. Neurology 2011, 76(7 Suppl. 2):S64-S66.
41. Camdessanche J.P., et al. Brain immunohistopathological study in a patient with anti-NMDAR encephalitis. Eur J Neurol 2011, 18(6):929-931.
42. Martinez-Hernandez E., et al. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology 2011, 77(6):589-593.
43. Bien C.G., et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 2012, 135(Pt 5):1622-1638.
44. Kumar M.A., et al. Anti-N-methyl-d-aspartate receptor encephalitis during pregnancy. Arch Neurol 2010, 67(7):884-887.
45. McCarthy A., et al. Anti-NMDA receptor encephalitis with associated catatonia during pregnancy. J Neurol 2012, 259(12):2632-2635.
46. Ito Y., et al. Anti-NMDA receptor encephalitis during pregnancy. Rinsho Shinkeigaku 2010, 50(2):103-107.
47. Magley J., et al. Pregnancy outcome in anti-N-methyl-d-aspartate receptor encephalitis. Obstet Gynecol 2012, 120(2 Pt 2):480-483.
48. Pruss H., et al. Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology 2010, 75(19):1735-1739.
49. Zhang Q., et al. Suppression of synaptic plasticity by cerebrospinal fluid from anti-NMDA receptor encephalitis patients. Neurobiol Dis 2012, 45(1):610-615.
50. Jantzen S.U., et al. In vitro neuronal network activity in NMDA receptor encephalitis. BMC Neurosci 2013, 14:17.
51. Rubio-Agusti I., et al. Isolated hemidystonia associated with NMDA receptor antibodies. Mov Disord 2011, 26(2):351-352.
52. Manto M., et al. In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction. Orphanet J Rare Dis 2010, 5:31.
53. Manto M., et al. Afferent facilitation of corticomotor responses is increased by IgGs of patients with NMDA-receptor antibodies. J Neurol 2011, 258(1):27-33.
54. Lai M., et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009, 65(4):424-434.
55. Graus F., et al. The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology 2010, 74(10):857-859.
56. Wei Y.C., et al. Rapid progression and brain atrophy in anti-AMPA receptor encephalitis. J Neuroimmunol 2013, 261(1-2):129-133.
57. Anggono V., Huganir R.L. Regulation of AMPA receptor trafficking and synaptic plasticity. Curr Opin Neurobiol 2012, 22(3):461-469.
58. Lu W., et al. Subunit composition of synaptic AMPA receptors revealed by a single-cell genetic approach. Neuron 2009, 62(2):254-268.
59. 2+-permeable AMPA receptors in synaptic plasticity and neuronal death. Trends Neurosci 2007, 30(3):126-134.
60. Palmer C.L., Cotton L., Henley J.M. The molecular pharmacology and cell biology of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Pharmacol Rev 2005, 57(2):253-277.
61. Czondor K., Thoumine O. Biophysical mechanisms regulating AMPA receptor accumulation at synapses. Brain Res Bull 2013, 93:57-68.
62. Rogers S.W., et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 1994, 265(5172):648-651.
63. Mantegazza R., et al. Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. J Neuroimmunol 2002, 131(1-2):179-185.
64. Watson R., et al. Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis. Neurology 2004, 63(1):43-50.
65. Wiedholz L.M., et al. Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and 'schizophrenia-related' behaviors. Mol Psychiatry 2008, 13(6):631-640.
66. Barkus C., et al. Do GluA1 knockout mice exhibit behavioral abnormalities relevant to the negative or cognitive symptoms of schizophrenia and schizoaffective disorder?. Neuropharmacology 2012, 62(3):1263-1272.
67. Mead A.N., et al. AMPA receptor GluR2, but not GluR1, subunit deletion impairs emotional response conditioning in mice. Behav Neurosci 2006, 120(2):241-248.
68. Mead A.N., Stephens D.N. Involvement of AMPA receptor GluR2 subunits in stimulus-reward learning: evidence from glutamate receptor gria2 knock-out mice. J Neurosci 2003, 23(29):9500-9507.
69. Stone T.W., Addae J.I. The pharmacological manipulation of glutamate receptors and neuroprotection. Eur J Pharmacol 2002, 447(2-3):285-296.
70. Hutchinson M., et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology 2008, 71(16):1291-1292.
71. Mas N., et al. Antiglycine-receptor encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 2011, 82(12):1399-1401.
72. Piotrowicz A., et al. A case of glycine-receptor antibody-associated encephalomyelitis with rigidity and myoclonus (PERM): clinical course, treatment and CSF findings. J Neurol 2011, 258(12):2268-2270.
73. Turner M.R., et al. Progressive encephalomyelitis with rigidity and myoclonus: glycine and NMDA receptor antibodies. Neurology 2011, 77(5):439-443.
74. Iizuka T., et al. Glycine receptor antibodies are detected in progressive encephalomyelitis with rigidity and myoclonus (PERM) but not in saccadic oscillations. J Neurol 2012, 259(8):1566-1573.
75. Clerinx K., et al. Progressive encephalomyelitis with rigidity and myoclonus: resolution after thymectomy. Neurology 2011, 76(3):303-304.
76. McKeon A., et al. Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol 2013, 70(1):44-50.
77. Damasio J., et al. Progressive encephalomyelitis with rigidity and myoclonus: the first pediatric case with glycine receptor antibodies. JAMA Neurol 2013, 1-4.
78. De Blauwe S.N., Santens P., Vanopdenbosch L.J. Anti-glycine receptor antibody mediated progressive encephalomyelitis with rigidity and myoclonus associated with breast cancer. Case Rep Neurol Med 2013, 2013:589154.
79. Kyskan R., et al. Antiglycine receptor antibody and encephalomyelitis with rigidity and myoclonus (PERM) related to small cell lung cancer. BMJ Case Rep 2013, 2013.
80. Peeters E., et al. Supranuclear gaze palsy in glycine receptor antibody-positive progressive encephalomyelitis with rigidity and myoclonus. Mov Disord 2012, 27(14):1830-1832.
81. Dutertre S., Becker C.M., Betz H. Inhibitory glycine receptors: an update. J Biol Chem 2012, 287(48):40216-40223.
82. Dresbach T., et al. Molecular architecture of glycinergic synapses. Histochem Cell Biol 2008, 130(4):617-633.
83. Baer K., et al. Localization of glycine receptors in the human forebrain, brainstem, and cervical spinal cord: an immunohistochemical review. Front Mol Neurosci 2009, 2:25.
84. Lynch J.W. Molecular structure and function of the glycine receptor chloride channel. Physiol Rev 2004, 84(4):1051-1095.
85. Butler M.H., et al. Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in stiff-man syndrome. J Exp Med 1993, 178(6):2097-2106.
86. Butler M.H., et al. Autoimmunity to gephyrin in stiff-man syndrome. Neuron 2000, 26(2):307-312.
87. De Camilli P., et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of stiff-man syndrome with breast cancer. J Exp Med 1993, 178(6):2219-2223.
88. Holmoy T., Geis C. The immunological basis for treatment of stiff person syndrome. J Neuroimmunol 2011, 231(1-2):55-60.
89. Bakker M.J., et al. Startle syndromes. Lancet Neurol 2006, 5(6):513-524.
90. Schaefer N., Vogel N., Villmann C. Glycine receptor mutants of the mouse: what are possible routes of inhibitory compensation?. Front Mol Neurosci 2012, 5:98.
91. Parker A.J., et al. Strychnine poisoning: gone but not forgotten. Emerg Med J 2011, 28(1):84.
92. Lancaster E., et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology 2011, 77(18):1698-1701.
93. Marignier R., et al. Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease?. Arch Neurol 2010, 67(5):627-630.
94. Iorio R., et al. Cerebellar degeneration associated with mGluR1 autoantibodies as a paraneoplastic manifestation of prostate adenocarcinoma. J Neuroimmunol 2013, 263(1-2):155-158.
95. Mat A., et al. Ophelia syndrome with metabotropic glutamate receptor 5 antibodies in CSF. Neurology 2013, 80(14):1349-1350.
96. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997, 37:205-237.
97. Enz R. Structure of metabotropic glutamate receptor C-terminal domains in contact with interacting proteins. Front Mol Neurosci 2012, 5:52.
98. Nusser Z., et al. Subsynaptic segregation of metabotropic and ionotropic glutamate receptors as revealed by immunogold localization. Neuroscience 1994, 61(3):421-427.
99. Kano M., Hashimoto K., Tabata T. Type-1 metabotropic glutamate receptor in cerebellar Purkinje cells: a key molecule responsible for long-term depression, endocannabinoid signalling and synapse elimination. Philos Trans R Soc Lond B Biol Sci 2008, 363(1500):2173-2186.
100. Jin Y., et al. Long-term depression of mGluR1 signaling. Neuron 2007, 55(2):277-287.
101. Ichise T., et al. mGluR1 in cerebellar Purkinje cells essential for long-term depression, synapse elimination, and motor coordination. Science 2000, 288(5472):1832-1835.
102. Batchelor A.M., et al. Pharmacological characterization of synaptic transmission through mGluRs in rat cerebellar slices. Neuropharmacology 1997, 36(3):401-403.
103. Hoftberger R., et al. Patient with homer-3 antibodies and cerebellitis. JAMA Neurol 2013, 70(4):506-509.
104. Aiba A., et al. Deficient cerebellar long-term depression and impaired motor learning in mGluR1 mutant mice. Cell 1994, 79(2):377-388.
105. Conti V., et al. crv4, a mouse model for human ataxia associated with kyphoscoliosis caused by an mRNA splicing mutation of the metabotropic glutamate receptor 1 (Grm1). Int J Mol Med 2006, 18(4):593-600.
106. Sachs A.J., et al. The mouse mutants recoil wobbler and nmf373 represent a series of Grm1 mutations. Mamm Genome 2007, 18(11):749-756.
107. Pietraszek M., et al. mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition. Neuropharmacology 2005, 49(1):73-85.
108. Coesmans M., et al. Mechanisms underlying cerebellar motor deficits due to mGluR1-autoantibodies. Ann Neurol 2003, 53(3):325-336.
109. Boronat A., et al. GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology 2011, 76(9):795-800.
110. Jeffery O.J., et al. GABAB receptor autoantibody frequency in service serologic evaluation. Neurology 2013, 81(10):882-887.
111. Hoftberger R., et al. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology 2013, 81(17):1500-1506.
112. Bettler B., et al. Molecular structure and physiological functions of GABA(B) receptors. Physiol Rev 2004, 84(3):835-867.
113. Benarroch E.E. GABAB receptors: structure, functions, and clinical implications. Neurology 2012, 78(8):578-584.
114. Pinard A., Seddik R., Bettler B. GABAB receptors: physiological functions and mechanisms of diversity. Adv Pharmacol 2010, 58:231-255.
115. Benke D., Zemoura K., Maier P.J. Modulation of cell surface GABA(B) receptors by desensitization, trafficking and regulated degradation. World J Biol Chem 2012, 3(4):61-72.
116. Vigot R., et al. Differential compartmentalization and distinct functions of GABAB receptor variants. Neuron 2006, 50(4):589-601.
117. Schuler V., et al. Epilepsy, hyperalgesia, impaired memory, and loss of pre- and postsynaptic GABA(B) responses in mice lacking GABA(B(1)). Neuron 2001, 31(1):47-58.
118. Mombereau C., et al. Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology 2004, 29(6):1050-1062.
119. Gambardella A., et al. GABA(B) receptor 1 polymorphism (G1465A) is associated with temporal lobe epilepsy. Neurology 2003, 60(4):560-563.
120. Wang X., et al. Association between the gamma-aminobutyric acid type B receptor 1 and 2 gene polymorphisms and mesial temporal lobe epilepsy in a Han Chinese population. Epilepsy Res 2008, 81(2-3):198-203.
121. Lancaster E., Dalmau J. Neuronal autoantigens-pathogenesis, associated disorders and antibody testing. Nat Rev Neurol 2012, 8(7):380-390.
122. Dale R.C., et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain 2012, 135(Pt 11):3453-3468.
123. Brimberg L., et al. Behavioral, pharmacological, and immunological abnormalities after streptococcal exposure: a novel rat model of Sydenham chorea and related neuropsychiatric disorders. Neuropsychopharmacology 2012, 37(9):2076-2087.
124. Ben-Pazi H., Stoner J.A., Cunningham M.W. Dopamine receptor autoantibodies correlate with symptoms in Sydenham's chorea. PLoS One 2013, 8(9):e73516.
125. Seeman P., et al. Dopamine D2 and D3 receptors in human putamen, caudate nucleus, and globus pallidus. Synapse 2006, 60(3):205-211.
126. Iversen S.D., Iversen L.L. Dopamine: 50years in perspective. Trends Neurosci 2007, 30(5):188-193.
127. Beaulieu J.M., Gainetdinov R.R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011, 63(1):182-217.
128. Baik J.H., et al. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 1995, 377(6548):424-428.
129. Vincent A. Autoimmune channelopathies: John Newsom-Davis's work and legacy. A summary of the Newsom-Davis memorial lecture 2008. J Neuroimmunol 2008, 201-202:245-249.
130. Tan K.M., et al. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 2008, 70(20):1883-1890.
131. + channels are implicated in neuromyotonia. Ann Neurol 1997, 41(2):238-246.
132. + channels: subunit specificity correlates with clinical manifestations. Brain 2006, 129(Pt 6):1570-1584.
133. Sinha S., et al. Autoimmune aetiology for acquired neuromyotonia (Isaacs' syndrome). Lancet 1991, 338(8759):75-77.
134. + channels of peripheral nerves. Ann Neurol 1995, 38(5):714-722.
135. Fu W.M., Lin R.H., Lin-Shiau S.Y. Study on the neuromuscular action of 4-aminopyridine in the mouse diaphragm. Arch Int Pharmacodyn Ther 1987, 289(2):198-211.
136. Roper J., Schwarz J.R. Heterogeneous distribution of fast and slow potassium channels in myelinated rat nerve fibres. J Physiol 1989, 416:93-110.
137. Irani S.R., et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010, 133(9):2734-2748.
138. Lancaster E., et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 2011, 69(2):303-311.
139. Lai M., et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010, 9(8):776-785.
140. Herranz-Perez V., et al. Regional distribution of the leucine-rich glioma inactivated (LGI) gene family transcripts in the adult mouse brain. Brain Res 2010, 1307:177-194.
141. Leonardi E., et al. A computational model of the LGI1 protein suggests a common binding site for ADAM proteins. PLoS One 2011, 6(3):e18142.
142. Sirerol-Piquer M.S., et al. The epilepsy gene LGI1 encodes a secreted glycoprotein that binds to the cell surface. Hum Mol Genet 2006, 15(23):3436-3445.
143. Morante-Redolat J.M., et al. Mutations in the LGI1/Epitempin gene on 10q24 cause autosomal dominant lateral temporal epilepsy. Hum Mol Genet 2002, 11(9):1119-1128.
144. Ogawa Y., et al. ADAM22, a Kv1 channel-interacting protein, recruits membrane-associated guanylate kinases to juxtaparanodes of myelinated axons. J Neurosci 2010, 30(3):1038-1048.
145. Schulte U., et al. The epilepsy-linked Lgi1 protein assembles into presynaptic Kv1 channels and inhibits inactivation by Kvbeta1. Neuron 2006, 49(5):697-706.
146. Han K., Kim E. Synaptic adhesion molecules and PSD-95. Prog Neurobiol 2008, 84(3):263-283.
147. Irani S.R., et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol 2012, 72(2):241-255.
148. Chabrol E., et al. Electroclinical characterization of epileptic seizures in leucine-rich, glioma-inactivated 1-deficient mice. Brain 2010, 133(9):2749-2762.
149. Nobile C., et al. LGI1 mutations in autosomal dominant and sporadic lateral temporal epilepsy. Hum Mutat 2009, 30(4):530-536.
150. Irani S.R., et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011, 69(5):892-900.
151. Andrade D.M., et al. Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis?. Neurology 2011, 76(15):1355-1357.
152. Schultze-Amberger J., Pehl D., Stenzel W. LGI-1-positive limbic encephalitis: a clinicopathological study. J Neurol 2012, 259(11):2478-2480.
153. Park D.C., et al. An autopsy case of limbic encephalitis with voltage-gated potassium channel antibodies. Eur J Neurol 2007, 14(10):e5-e6.
154. + channels. Neuron 1999, 24(4):1037-1047.
155. + channels in myelinated axons depends on Caspr2 and TAG-1. J Cell Biol 2003, 162(6):1149-1160.
156. Horresh I., et al. Organization of myelinated axons by Caspr and Caspr2 requires the cytoskeletal adapter protein 4.1B. J Neurosci 2010, 30(7):2480-2489.
157. Strauss K.A., et al. Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2. N Engl J Med 2006, 354(13):1370-1377.
158. Becker E.B., et al. Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. J Neurol Neurosurg Psychiatry 2012, 83(4):437-440.
159. Becker E.B., et al. Candidate screening of the TRPC3 gene in cerebellar ataxia. Cerebellum 2011, 10(2):296-299.
160. Boronat A., et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol 2013, 73(1):120-128.
161. Kim J., et al. Kv4 accessory protein DPPX (DPP6) is a critical regulator of membrane excitability in hippocampal CA1 pyramidal neurons. J Neurophysiol 2008, 100(4):1835-1847.
162. + channels. Neuron 2003, 37(3):449-461.
163. Sun W., et al. DPP6 establishes the A-type K(+) current gradient critical for the regulation of dendritic excitability in CA1 hippocampal neurons. Neuron 2011, 71(6):1102-1115.
164. Titulaer M.J., Lang B., Verschuuren J.J. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 2011, 10(12):1098-1107.
165. Burk K., et al. Antineuronal antibodies in sporadic late-onset cerebellar ataxia. J Neurol 2010, 257(1):59-62.
166. Lorenzoni P.J., et al. Cerebellar ataxia in non-paraneoplastic Lambert-Eaton myasthenic syndrome. J Neurol Sci 2008, 270(1-2):194-196.
167. Graus F., et al. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 2002, 59(5):764-766.
168. Mason W.P., et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 1997, 120(Pt 8):1279-1300.
169. 2+ channels mediating synaptic transmission at the calyx of Held of mice. J Physiol 2005, 568(Pt 1):199-209.
170. Westenbroek R.E., et al. Immunochemical identification and subcellular distribution of the alpha 1A subunits of brain calcium channels. J Neurosci 1995, 15(10):6403-6418.
171. Catterall W.A. Voltage-gated calcium channels. Cold Spring Harb Perspect Biol 2011, 3(8):a003947.
172. Rajakulendran S., Kaski D., Hanna M.G. Neuronal P/Q-type calcium channel dysfunction in inherited disorders of the CNS. Nat Rev Neurol 2012, 8(2):86-96.
173. Fukuda T., et al. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol 2003, 53(1):21-28.
174. Blumenfeld A.M., et al. Coexistence of Lambert-Eaton myasthenic syndrome and subacute cerebellar degeneration: differential effects of treatment. Neurology 1991, 41(10):1682-1685.
175. 2+ currents and mimics cerebellar ataxia in vivo. Proc Natl Acad Sci U S A 2008, 105(7):2705-2710.
176. Komai K., Iwasa K., Takamori M. Calcium channel peptide can cause an autoimmune-mediated model of Lambert-Eaton myasthenic syndrome in rats. J Neurol Sci 1999, 166(2):126-130.
177. Martin-Garcia E., et al. Intrathecal injection of P/Q type voltage-gated calcium channel antibodies from paraneoplastic cerebellar degeneration cause ataxia in mice. J Neuroimmunol 2013, 261(1-2):53-59.
178. Eiraku M., et al. Delta/notch-like epidermal growth factor (EGF)-related receptor, a novel EGF-like repeat-containing protein targeted to dendrites of developing and adult central nervous system neurons. J Biol Chem 2002, 277(28):25400-25407.
179. Tohgo A., et al. Impaired cerebellar functions in mutant mice lacking DNER. Mol Cell Neurosci 2006, 31(2):326-333.
180. Bernal F., et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003, 60(2):230-234.
181. Simonyi A., Schachtman T.R., Christoffersen G.R. Metabotropic glutamate receptor subtype 5 antagonism in learning and memory. Eur J Pharmacol 2010, 639(1-3):17-25.
182. Jarius S., et al. GABAB receptor antibodies in paraneoplastic cerebellar ataxia. J Neuroimmunol 2013, 256(1-2):94-96.
183. Wysota B., et al. Autoimmune gabab antibody encephalitis associated with non-malignant lung lesion. J Neurol Neurosurg Psychiatry 2013, 84(11):e2.
184. Tofaris G.K., et al. Immunotherapy-responsive chorea as the presenting feature of LGI1-antibody encephalitis. Neurology 2012, 79(2):195-196.
185. Klein C.J., et al. Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping. JAMA Neurol 2013, 70(2):229-234.
186. Krastinova E., et al. Treatment of limbic encephalitis with anti-glioma-inactivated 1 (LGI1) antibodies. J Clin Neurosci 2012, 19(11):1580-1582.
187. Balint B., et al. Caspr2 antibodies in limbic encephalitis with cerebellar ataxia, dyskinesias and myoclonus. J Neurol Sci 2013, 327(1-2):73-74.
188. Vincent A., Irani S.R. Caspr2 antibodies in patients with thymomas. J Thorac Oncol 2010, 5(10 Suppl. 4):S277-S280.
189. Ogawa E., et al. VGCC antibody-positive paraneoplastic cerebellar degeneration presenting with positioning vertigo. Neurol Sci 2011, 32(6):1209-1212.
190. Shams'ili S., et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003, 126(Pt 6):1409-1418.
191. Briani C., et al. Spectrum of paraneoplastic disease associated with lymphoma. Neurology 2011, 76(8):705-710.
192. Graus F., et al. Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. J Neuroimmunol 1997, 74(1-2):55-61.